These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37384864)

  • 1. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration.
    Bailey CN; Martin BJ; Petkov VI; Schussler NC; Stevens JL; Bentler S; Cress RD; Doherty JA; Durbin EB; Gomez SL; Gonsalves L; Hernandez BY; Liu L; Morawski BM; Schymura MJ; Schwartz SM; Ward KC; Wiggins C; Wu XC; Goldberg MS; Siegel JJ; Cook RW; Covington KR; Kurley SJ
    JCO Precis Oncol; 2023 Jun; 7():e2300044. PubMed ID: 37384864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
    Wisco OJ; Marson JW; Litchman GH; Brownstone N; Covington KR; Martin BJ; Quick AP; Siegel JJ; Caruso HG; Cook RW; Winkelmann RR; Rigel DS
    Melanoma Res; 2022 Apr; 32(2):98-102. PubMed ID: 35254332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 31-Gene Expression Profile Test Outperforms AJCC in Stratifying Risk of Recurrence in Patients with Stage I Cutaneous Melanoma.
    Podlipnik S; Martin BJ; Morgan-Linnell SK; Bailey CN; Siegel JJ; Petkov VI; Puig S
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
    Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
    Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
    Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
    J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test.
    Ahmed K; Siegel JJ; Morgan-Linnell SK; LiPira K
    Cancer Med; 2023 Jan; 12(2):2008-2015. PubMed ID: 35915969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of Prognosis in Invasive Cutaneous Melanoma: An Independent Study of the Accuracy of a Gene Expression Profile Test.
    Greenhaw BN; Zitelli JA; Brodland DG
    Dermatol Surg; 2018 Dec; 44(12):1494-1500. PubMed ID: 29994951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
    BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.
    Hsueh EC; DeBloom JR; Lee JH; Sussman JJ; Covington KR; Caruso HG; Quick AP; Cook RW; Slingluff CL; McMasters KM
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
    Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
    Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma.
    Jarell A; Skenderis B; Dillon LD; Dillon K; Martin B; Quick AP; Siegel JJ; Rackley BB; Cook RW
    Future Oncol; 2021 Dec; 17(36):5023-5031. PubMed ID: 34587770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
    Gastman BR; Gerami P; Kurley SJ; Cook RW; Leachman S; Vetto JT
    J Am Acad Dermatol; 2019 Jan; 80(1):149-157.e4. PubMed ID: 30081113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
    Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
    J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Stratification of Patients with Stage I Cutaneous Melanoma Using 31-Gene Expression Profiling.
    Martin BJ; Covington KR; Quick AP; Cook RW
    J Clin Aesthet Dermatol; 2021 Sep; 14(9):E61-E63. PubMed ID: 34980974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using a 31-Gene Expression Profile Test to Stratify Patients with Stage I-II Cutaneous Melanoma According to Recurrence Risk: Update to a Prospective, Multicenter Study.
    Podlipnik S; Boada A; López-Estebaranz JL; Martín-González MM; Redondo P; Martin B; Quick AP; Bailey CN; Kurley SJ; Cook RW; Puig S
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 31-GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort.
    Pazhava A; Kim YH; Jing FZ; Pittelkow MR
    Int J Dermatol; 2024 Aug; ():. PubMed ID: 39154363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma.
    Miguez S; Lee RY; Chan AX; Demkowicz PC; Jones BSCL; Long CP; Abramson DH; Bosenberg M; Sznol M; Kluger H; Goldbaum MH; Francis JH; Pointdujour-Lim R; Bakhoum MF
    Ophthalmology; 2023 Jun; 130(6):598-607. PubMed ID: 36739981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma.
    Scott AM; Dale PS; Conforti A; Gibbs JN
    Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.
    Yamamoto M; Sickle-Santanello B; Beard T; Essner R; Martin B; Bailey CN; Guenther JM
    Curr Med Res Opin; 2023 Mar; 39(3):417-423. PubMed ID: 36617959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
    Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
    J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.